Insmed Names Ex-Sanofi CEO Paul Hudson And Verily Health CFO Utpal Koppikar To Its Board

Each new independent director gets restricted stock units with a grant-date fair value of about $585,000, plus a committee seat, an 8-K shows.

Share
Insmed Names Ex-Sanofi CEO Paul Hudson And Verily Health CFO Utpal Koppikar To Its Board

Insmed appointed two independent directors on October 16: Paul Hudson, Sanofi's CEO from September 2019 through February 2026, and Utpal Koppikar, chief financial officer of Verily Health. The appointments take effect October 19, according to an 8-K, and the company announced them Tuesday.

Seats, classes and pay

Hudson, a Class II director, joins the Compensation Committee. Koppikar, a Class I director, joins the Audit Committee. Both stand for election at the 2027 annual meeting of shareholders.

Each man receives an annual cash retainer of $65,000, prorated this year from the appointment date. Each also gets an extra $12,500 annual retainer for his committee seat, likewise prorated.

Each also gets restricted stock units, shares that are delivered over time, with a grant-date fair value of about $585,000. They vest in equal parts on each of the first three one-year anniversaries of the award, provided the director is still serving on each date.

The filing says no arrangement exists between either man and any person under which he was chosen. It also says neither has a material interest in a transaction requiring disclosure under Item 404(a) of Regulation S-K.

Who the directors are

Hudson ran Novartis Pharmaceuticals from 2016 to 2019, before Sanofi. Earlier he held senior roles at AstraZeneca, including president of AstraZeneca United States.

Koppikar has been CFO of Verily Health since April 2023, where he oversees finance, real estate and workplace services, and corporate development. He was CFO of Atara Biotherapeutics from 2018 to 2023 and held finance posts at Gilead Sciences and Amgen. He sits on the board of C4 Therapeutics.

Will Lewis, Insmed's chair and CEO, said in the press release that Hudson's experience at large biopharma organizations "will be invaluable as we continue to execute our global growth strategy." Hudson said he hoped to apply his experience in "global commercial strategy and organizational transformation."

Both seats go before shareholders at Insmed's 2027 annual meeting.

Sources

More on Insmed

All Insmed (INSM) coverage →